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Phosphoinositide 3-kinases (PI-3Ks) are key
enzymes for cell development, activation, and
survival. Here we showed that PI-3K class IB
and class IA catalytic subunits, p110g and
p110d, played a crucial role in the development
and functions of murine NK cells. p110g defi-
ciency and impairment of G protein-coupled re-
ceptor (GPRC) signaling prevented full NK cell
maturation. Concomitant loss of p110g and
p110d exacerbated this defect, resulting in
a very small population of NK cells with a highly
immature phenotype in the bone marrow and
periphery. Moreover, combined p110g and
p110d signals were required for cytotoxicity
and activation of the kinase ERK during NK
cell-target cell interaction. p110gplayed amajor
role in receptor-induced interferon-g (IFN-g)
production through a pathway that involved
the kinase ERK and 5-Lipoxigenase, which
most likely generates lipid mediators activating
GPRCs. Conversely, PI3Ks negatively regulated
interleukin-12 (IL-12) and IL-18-induced IFN-g
by modulating p38 kinase activation. Our data
shed light on themultiple intersecting pathways
through which PI3Ks control NK cell-mediated
innate responses.
INTRODUCTION
Phosphoinositide 3-kinases (PI3Ks) include a family of en-
zymes that catalyze the phosphorylation of the 30 hydroxyl
group of phosphoinositides (PIs), such as PI(4,5)P2 (PIP2),
generating PI(3,4,5)P3 (PIP3). PIP3 acts as second mes-
senger by binding pleckstrin homology (PH) domain-
containing proteins, including PLCg1 and PLCg2, the
Vav proteins, and TEC family kinases, which are then214 Immunity 27, 214–227, August 2007 ª2007 Elsevier Inc.recruited to the plasma membrane and become activated,
prompting multiple cellular responses (Deane and
Fruman, 2004; Koyasu, 2003; Vanhaesebroeck et al.,
2001). In natural killer (NK) cells, PI3Ks are common
signaling mediators downstream of receptors that trigger
cytotoxicity. The receptor NKG2D signals through a trans-
membrane adaptor, DAP10, which contains a YINM cyto-
plasmic motif that directly recruits PI3K (Lanier, 2003) as
well as the Grb2-Vav1 signaling complex (Billadeau
et al., 2003; Cella et al., 2004; Upshaw et al., 2006). The
receptors NKRP1C (NK1.1), Ly49D, and CD16 deliver
intracellular signals through alternative adaptors such as
CD3z, FcRg, and DAP12 (Lanier, 2003; Vivier et al.,
2004). These adaptors contain cytoplasmic tyrosine-
based activation motifs (ITAM) that act as docking sites
for the protein tyrosine kinases Syk and Zap70. These ty-
rosine kinases in turn recruit and activate PI3Ks and other
signaling mediators, such as PLCg1, PLCg2, Vav2, Vav3,
LAT, and NTAL.
Biochemical studies have shown that CD16, NKG2D,
and other NK cell receptors activate PI3Ks and their
downstream targets (Billadeau et al., 2003; Bonnema
et al., 1994; Cerboni et al., 1998; Jiang et al., 2002; Lanier,
2003; Vivier et al., 2004). Moreover, treatment of NK cells
with pharmacological inhibitors of PI3Ks reduces NK cell-
mediated cytotoxicity against various tumor-transformed
cells (Bonnema et al., 1994; Jiang et al., 2000; Zhong
et al., 2002; Zompi et al., 2003). Finally, experiments
employing pharmacological inhibitors and dominant-
negative forms of downstream signaling target molecules
have shown that PI3Ks trigger cytotoxicity through
sequential activation of the small G protein Rac1, the
p21-activated kinase 1 (PAK1), MEK, and ERK1 and
ERK2 (Jiang et al., 2000). However, whether PI3Ks are ab-
solutely required for NK cell-mediated cytotoxicity is not
known. In fact, pharmacological inhibition of PI3Ks did
not block lysis of certain tumor cells (Bonnema et al.,
1994). Moreover, inhibition of PI3Ks reduced, but did
not abrogate, NKG2D-DAP10-mediated killing (Upshaw
et al., 2006) and did not affect NKG2D-DAP10-mediated
phosphorylation of PLCg2 or Vav1 (Billadeau et al.,
2003). In addition, DAP10 can signal independently of
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2006). Thus, NK cell-mediated lysis of target cells may
variably rely on PI3Ks, depending upon the specific NK
cell receptors involved in recognition and their signaling
pathways. In addition to cytotoxicity, NK cells provide
a major source of interferon-g (IFN-g). IL-12 and IL-18
are the major inducers of IFN-g secretion (Biron et al.,
1999). Activating receptors that signal through ITAMs
also stimulate IFN-g secretion (Zompi et al., 2003),
whereas the DAP10 pathway alone does not (Zompi
et al., 2003). Whether PI3Ks are required for IFN-g secre-
tion by NK cells has not been investigated.
Although PI3Ks include multiple members (Deane and
Fruman, 2004; Koyasu, 2003; Vanhaesebroeck et al.,
2001), it is not known which subunits are required for NK
cell functions. Leukocytes express class IA PI3Ks, which
consist of a p110 catalytic subunit associated with
a p85, p55, or p50 regulatory subunit. The p110 catalytic
subunits are encoded by three distinct genes, Pik3ca,
Pik3cb, and Pik3cd. Leukocytes also express class IB
PI3Ks, which consist of one catalytic subunit, p110g,
associated with two regulatory subunits, p101 (Deane
and Fruman, 2004; Koyasu, 2003; Vanhaesebroeck
et al., 2001) and p84 (Suire et al., 2005). The class IA
PI3Ks are triggered by a variety of cell-surface receptors,
whereas the class IB PI3K is activated by G protein bg
subunits and hence signals downstream of G protein-cou-
pled receptors (GPCRs) (Deane and Fruman, 2004;
Koyasu, 2003; Vanhaesebroeck et al., 2001). Among the
various mice in which class IA or class IB PI3Ks have
been targeted, Pik3ca/ and Pik3cb/ mice die in utero
(Vanhaesebroeck et al., 2005). In contrast, Pik3cg/ and
Pik3cd/ mice develop normally, allowing analysis of the
immune system in the absence of these PI3K subunits.
Granulocyte and macrophage migration as well as T cell
development, activation, and homing are defective in
Pik3cg/ mice (Hirsch et al., 2000; Li et al., 2000; Puri
et al., 2005; Reif et al., 2004; Sasaki et al., 2000).
Pik3cd/ mice have defects in B cell receptor signaling
and B cell chemotaxis (Clayton et al., 2002; Jou et al.,
2002; Reif et al., 2004), whereas mice expressing a catalyti-
cally inactive p110d also have impaired T cell receptor
(TCR) signaling (Okkenhaug et al., 2002). Profound
defects in T cell development, TCR signaling, and thymo-
cyte survival are evident in mice lacking both Pik3cg/
and Pik3cd/ in comparison to singly deficient mice,
indicating a synergistic relationship between these two
distinct p110 isoforms in antigen receptor signaling
(Swat et al., 2006; Webb et al., 2005).
In this study, we determined the role of p110g and p110d
catalytic subunits in NK cell function by using Pik3cg/,
Pik3cd/, and Pik3cg/ Pik3cd/ double-deficient
mice (Pik3cg/Pik3cd/). Our results show that p110g
has a critical nonredundant role in NK cell development
and ITAM-induced IFN-g secretion. Moreover, we show
that p110g and p110d synergize in directing NK cell devel-
opment and cytotoxicity, demonstrating that the signaling
pathways mediated by these distinct PI3K subunits inter-
sect in a functionally significant manner.RESULTS
p110g and p110d Signaling Is Required for Murine
NK Cell Development
To understand how PI3Ks function in NK cell physiology,
we first determined which class I PI3K subunits are ex-
pressed by NK cells. Immunoblot analysis indicated that
NK cells express p110g and p110d as well as the ubiqui-
tously distributed p110a and p110b subunits (Figure 1A).
To address the role of p110g and p110d in NK cells devel-
opment and function, we analyzed Pik3cg/, Pik3cd/,
and Pik3cg/Pik3cd/ mice. We initially compared the
numbers and percentages of NK cells in the spleen of
Pik3cg/, Pik3cd/, Pik3cg/Pik3cd/, and WT
mice. NK cells were normally represented in spleens of
Pik3cg/ and Pik3cd/ mice (Figure S1 in the Supple-
mental Data available online). However, Pik3cg/
Pik3cd/ spleens had a 60%–70% reduction in the per-
centage of NK cells (Figures 1B and 1C). Moreover, the
total number of splenocytes in Pik3cg/Pik3cd/ mice
was approximately 50% less than in WT mice, as previ-
ously described (Swat et al., 2006; Webb et al., 2005);
therefore, the absolute number of splenic NK cells was se-
verely reduced. Numbers and percentages of CD3+ T cells
were also reduced, as previously described (Swat et al.,
2006; Webb et al., 2005), whereas the percentage of
NK1.1+ CD3+ T cells was slightly increased (Figure 1B
and data not shown). However, these NK1.1+ CD3+ cells
were not canonical CD1d-restricted Va14 NKT cells, as
shown by the fact that they did not bind a-GalCer-loaded
CD1d tetramers (data not shown). Altogether, these data
strongly suggested that lack of both p110g and p110d
affects NK cell development.
During development, NK cells acquire activating and
inhibitory receptors, cytokine receptors, and adhesion
molecules in an orderly fashion (Di Santo, 2006; Haya-
kawa and Smyth, 2006; Kim et al., 2002; Lian and Kumar,
2002; Raulet et al., 2001). Committed NK cell progenitors
(NKP) initially express the b subunit of IL-2R and IL-15R
(CD122), the receptor 2B4, as well as the a chain of
IL-7R (CD127) and c-kit (CD117). Subsequently, NK cell
precursors attain an immature NK cell phenotype, ex-
pressing the receptor NKRP1C (NK1.1 on the C57BL/6
background), the integrin CD49b (DX5), the costimulatory
molecule CD27, and the activating and inhibitory NKG2
receptors (NKG2D and NKG2A, C, E). Upon maturation,
NK cells downregulate CD127, CD117, and CD27 and
acquire high expression of aM integrin (CD11b) as well
as activating and inhibitory Ly49 receptors (Ly49D,
Ly49H, Ly49A, Ly49C, Ly49I). We found that Pik3cd/
splenic NK cells were phenotypically indistinguishable
from WT NK cells (Figure 2). Splenic NK cells from
Pik3cg/ mice contained substantially higher percent-
ages of CD117+, CD127+, and CD27+ NK cells and lower
percentages of 2B4+ NK cells than did splenic NK from
WT mice (Figure 2). However, Pik3cg/ NK cells
expressed CD11b and most of the Ly49 receptors just
like WT NK cells, with the exception of a slight reduction
in the number of Ly49C+ and Ly49I+ cells (Figure 2B).Immunity 27, 214–227, August 2007 ª2007 Elsevier Inc. 215
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PI3K in NK Cell Development and FunctionFigure 1. NK Cell Numbers Are Reduced in Spleens of Pik3cg/Pik3cd/ Mice
(A) Expression of p110a, p110b, p110g, and p110d in murine NK cells. Lysates of WT, Pik3cg/, Pik3cd/, and Pik3cg/Pik3cd/ NK cells were
analyzed by immunoblotting with anti-p110a, -p110b, -p110g, and -p110d as well as an ERK antibody, as loading control.
(B) Reduced numbers of NK1.1+CD3 NK cells in spleens of Pik3cg/Pik3cd/ mice. Splenocytes of WT andPik3cg/Pik3cd/mice were stained
with anti-NK1.1 and anti-CD3 and analyzed by flow cytometry.
(C) Statistical analysis of several mice (9/group) revealed a highly significant (p < 0.001) difference in NK cells percentages between WT and
Pik3cg/Pik3cd/ mice. g/, Pik3cg/; d/, Pik3cd/; g/ d/, Pik3cg/Pik3cd/.Remarkably, Pik3cg/Pik3cd/ mice had a much more
striking developmental defect than that observed in
Pik3cg/ mice (Figure 2). High percentages of Pik3cg/
Pik3cd/ NK cells expressed CD117 and CD127,
whereas about 40%–50% of cells had a CD27+ CD11b
immature phenotype (Figure 2C). Moreover, acquisition
of all Ly49 receptors was severely impaired (Figure 2B).
CD122, NK1.1, DX5, NKG2 receptors, and CD16 were
equally expressed on Pik3cg/Pik3cd/, Pik3cg/,
and WT NK cells (Figure 2). Analysis of bone-marrow NK
cells derived from Pik3cg/, Pik3cd/, Pik3cg/
Pik3cd/, and WT mice confirmed the phenotypic
abnormalities observed in splenic NK cells (Figure S2).
Therefore, these results are consistent with a striking
defect of NK cell maturation in the bone marrow and
spleen as a consequence of the combined loss of p110g
and p110d PI3K subunits. NK cell development is blocked
before the stage at which NK cells acquire Ly49 receptors.
Intrinsic Impairment of NK Cell Development
in Pik3cg/ and Pik3cg/Pik3cd/ Mice
To determine whether the defect of NK cell development
observed in Pik3cg/ and Pik3cg/Pik3cd/ was due
to an intrinsic NK cell defect or to a stromal cell defect
that secondarily impairs NK cell development, we gener-
ated hematopoietic chimeras by reconstituting irradiated
WT mice with Pik3cg/, Pik3cd/, Pik3cg/Pik3cd/,
or WT bone marrow. In these chimeras, NK cell progeni-
tors harbor the various PI3K-targeted mutations, whereas
stromal cells have normal PI3K functions. After 8–9 weeks,
NK cell numbers and phenotypes were analyzed in spleen
and bone marrow of transplanted mice. NK cells from216 Immunity 27, 214–227, August 2007 ª2007 Elsevier Inc.chimeric mice reconstituted with Pik3cg/ and Pik3cg/
Pik3cd/ bone-marrow cells had the same developmen-
tal defect observed in NK cells of Pik3cg/ and Pik3cg/
Pik3cd/ mice (Figure 3; Figure S3). In Pik3cg//WT
chimeras, NK cell numbers were slightly reduced and
the frequency of immature CD117+ CD127+ 2B4
Ly49C Ly49I NK cells was increased. In Pik3cg/
Pik3cd//WT chimeras, NK cell numbers were further
reduced and the increased frequency of immature NK
cells was paralleled by a strong reduction of CD11b+
Ly49+ mature NK cells. NK cells of chimeric mice reconsti-
tuted withPik3cd/ and WT bone-marrow cells had a nor-
mal phenotype (Figure 3; Figure S3). We conclude that the
impairment of NK cell development in Pik3cg/ and
Pik3cg/Pik3cd/ is due to an intrinsic NK cell defect
and cannot be attributed to altered PI3K activity in bone-
marrow stromal cells.
Pik3cg/Pik3cd/ NK Cells Have Reduced
Cytotoxicity
To examine the effector functions ofPik3cg/,Pik3cd/,
and Pik3cg/Pik3cd/ NK cells, splenic NK cells from
Pik3cg/, Pik3cd/, Pik3cg/Pik3cd/, and WT mice
were purified and tested ex vivo for cytotoxicity against
YAC-1 cells and RMAS cells transfected with Rae1g
(RMAS-Rae1g), which are recognized through NKG2D
(Lanier, 2003). Pik3cg/Pik3cd/ NK cells had markedly
reduced ability to lyse YAC-1 (Figure 4A) and Rae-1g-
RMAS (Figure S4A) cells in comparison to WT NK cells.
Pik3cg/ NK cells were slightly less lytic than WT NK
cells, whereas the cytotoxic activity of Pik3cd/ NK cells
was comparable to that of WT NK cells. The observed
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PI3K in NK Cell Development and FunctionFigure 2. Splenic NK Cells of Pik3cg/ and Pik3cg/Pik3cd/ Mice Have an Immature Phenotype
NK cells from WT, Pik3cg/, Pik3cg/Pik3cd/, and Pik3cd/ spleens were purified and stained for (A) CD122 (IL-2 and IL-15 receptor), CD117
(c-kit), CD127 (IL-7 receptor), DX5 (VLA-2), CD11b (aM integrin), 2B4, and CD16,CD32; (B) NKG2A,C,E, NKG2D, Ly49A, Ly49D, Ly49C,I, Ly49C,I,F,H;
and (C) CD27 and CD11b. Expression of the relevant markers is shown upon gating on NK1.1+ CD3 cells. We analyzed 6 mice/group with equivalent
results. Similar results were obtained by staining total splenocytes (data not shown). g/, Pik3cg/; d/, Pik3cd/; g/ d/,
Pik3cg/Pik3cd/.reductions in NK cell-mediated cytotoxicity in Pik3cg/
Pik3cd/ and Pik3cg/ mice could be explained by the
defect in NK cell development, as shown by the fact that
NK cells with an immature phenotype have been shown
to have lower intrinsic cytolytic capacity than that of
mature NK cells (Di Santo, 2006).
IL-2 activation of immature NK cells engenders normal
cytolytic capacity and normal expression of Ly49 recep-
tors (Di Santo, 2006). Therefore, we also tested IL-2-acti-
vated NK cells in our killing assays to determine whether
mechanisms other than NK cell immaturity contribute to
the defective cytotoxicity of Pik3cg/ and Pik3cg/Pik3cd/ NK cells. IL-2-activated NK cells purified from
Pik3cg/ and Pik3cg/Pik3cd/ mice proliferated
normally (Figure 4B), and at day 5–8 of culture had no
marked differences in perforin and granzyme B content
in comparison with those from WT mice (Figure 4C).
Many activating receptors involved in target cell recogni-
tion, such as NKG2D and CD16, were similarly expressed
on IL-2-activated Pik3cg/, Pik3cg/Pik3cd/, and WT
NK cells (Figure 4D). However, the percentages of Ly49+
cells in cultures of IL-2-activated Pik3cg/Pik3cd/ NK
cells remained quite low in comparison to those in WT
NK cell cultures (Figure 4D). We measured cytotoxicityImmunity 27, 214–227, August 2007 ª2007 Elsevier Inc. 217
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PI3K in NK Cell Development and FunctionFigure 3. The Developmental Defect of NK Cells in Pik3cg/ and Pik3cg/Pik3cd/ Mice Is NK Cell Intrinsic
(A and B) Phenotype of splenic NK cells from bone-marrow chimeras. Pik3cg/, Pik3cd/, Pik3cg/Pik3cd/, and WT bone-marrow cells were
transferred into lethally irradiated WT mice. Approximately 8–9 weeks after bone-marrow transfer, spleen NK cells were analyzed by flow cytometry.
The genotype of splenic cells was verified by monitoring in immunoblot analysis the expression of p110g and p110d. No endogenous p110g and/or
p110d were detected in Pik3cg//WT, Pik3cd//WT, and Pik3cg/Pik3cd//WT chimeras (data not shown). Data presented are represen-
tative of at least four independent mice/genotype.218 Immunity 27, 214–227, August 2007 ª2007 Elsevier Inc.
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tivated splenic NK cells against a panel of targets that in-
cluded not only YAC-1 and RMAS-Rae1g cells but also
Chinese Hamster Ovary (CHO) cells, which are recognized
through Ly49D-DAP12, and EL-4 cells coated with Thy1.2
antibody, which are recognized through CD16-FcRg
(Cella et al., 2004). IL-2-activated Pik3cg/Pik3cd/
NK cells were virtually unable to lyse CHO cells (Fig-
ure S4D), consistent with the loss of Ly49D expression.
Moreover, IL-2-activated Pik3cg/Pik3cd/ NK cells
lysed YAC-1 (Figure 4E), RMAS-Rae1g (Figure S4B), and
antibody-coated EL-4 cells (Figure S4C) less efficiently
than WT NK cells, suggesting that combined deficiency
of p110g and p110d affects NK cell cytotoxicity through
mechanisms independent of the developmental defect.
The lytic capacity of Pik3cg/ NK cells was slightly
reduced compared to that of WT NK cells (Figures 4A and
4E) and, consistent with this, pharmacological inhibitors
of p110g induced a slight reduction of YAC-1 (Figure 4F)
and RMAS-Rae1g (Figure S4E) cell lysis. The lytic activity
of Pik3cd/ NK cells was normal in all assays. Overall,
these results suggest that NK cell cytotoxicity involves
synergy between p110g and p110d signals. Therefore,
the reduced NK cell cytotoxicity observed in Pik3cg/
Pik3cd/ mice may be due not only to defective ac-
quisition of a full NK cell receptor repertoire but also to a
direct impact of combined p110g and p110d deficiency
on intracellular signals that trigger target cell lysis.
p110g and p110d Cooperate to Activate ERK1
and ERK2 in NK Cells
It has been shown that PI3K triggers human NK cell-medi-
ated cytotoxicity through sequential activation of Rac1,
PAK1, MEK, and ERK1 and ERK2 (Jiang et al., 2000).
Moreover, pharmacological blockade of ERK impairs NK
cell-mediated lysis of various target cells (Trotta et al.,
1998). Thus, the reduction in cytotoxicity observed in
Pik3cg/Pik3cd/ may be due to impaired ERK signal-
ing. To test this hypothesis, we analyzed signaling events
after conjugation of Pik3cg/, Pik3cd/, Pik3cg/
Pik3cd/, and WT NK cells with the target cell YAC-1.
ERK1 and ERK2 phosphorylation was evidently dimini-
shed when both catalytic subunits were missing
(Figure 5A). Pik3cg/Pik3cd/ NK cells also had de-
creased phosphorylation of AKT (Figure 5B), a down-
stream target of PI3Ks, confirming that a combined lack
of both catalytic subunits results in obvious impairment
of PI3K activity. In contrast, single ablation of p110g or
p110d did not cause any evident defect in ERK or Akt
phosphorylation (Figures 5A and 5B; data not shown).
Because it has been shown that MAPK p38 is also in-
volved in NK cell-mediated lysis of various target cells
(Trotta et al., 2000), we asked whether loss of p110g and
p110d has any impact on p38 activation. We found thatafter conjugation with the target cell YAC-1, Pik3cg/
and Pik3cg/Pik3cd/ NK cells had no marked reduc-
tion of p38 phosphorylation as compared to WT NK cells.
In fact, basal phosphorylation of p38 was slightly
increased in Pik3cg/Pik3cd/ NK cells (Figure 5C).
Moreover, we found that the p38 inhibitor SB203580 did
not inhibit cytotoxicity against YAC-1 and RMAS-Rae1g
cells (Figure 5D; data not shown). We conclude that reduc-
tion of cytotoxicity in Pik3cg/Pik3cd/ NK cells may be
in part due to defective activation of ERK1 and ERK2 but
not reduced p38 activation.
Activating Receptors Trigger IFN-g Secretion
through a p110g-Dependent Pathway
Activating receptors that signal through ITAMs stimulate
not only cytotoxicity but also IFN-g secretion. To investi-
gate the impact of p110g and p110d on ITAM-mediated
secretion of IFN-g, we stimulated Pik3cg/, Pik3cd/,
Pik3cg/Pik3cd/, and WT splenocytes by crosslinking
the receptor NK1.1, which signals through FcRg (Arase
et al., 1997). We then measured production of IFN-g in
DX5+CD3 NK cells by intracellular staining and cytomet-
ric bead arrays. NK1.1 stimulation of Pik3cg/ and
Pik3cg/Pik3cd/ NK cells induced little or no increase
in IFN-g production, as compared to Pik3cd/ and WT
NK cells (Figures 6A and 6B). Because stimulation through
NK1.1 alone induces limited amounts of IFN-g, NK1.1
stimulations were performed also in the presence of low
concentrations of IL-12 and IL-18, which considerably
amplify NK1.1-induced IFN-g production (Ortaldo et al.,
2006). Even in the presence of IL-12 and IL-18 costimuli,
crosslinking of NK1.1 induced less IFN-g production in
Pik3cg/ and Pik3cg/Pik3cd/ NK cells as compared
to Pik3cd/ and WT NK cells (Figure 6C). The defect in
IFN-g production observed in Pik3cg/ NK cells was as
profound as the reduction observed in Pik3cg/
Pik3cd/ NK cells. Thus, p110g plays a major role in
ITAM-mediated secretion of IFN-g. Although defective
IFN-g secretion by Pik3cg/ and Pik3cg/Pik3cd/
NK cells may be partly a consequence of their immature
phenotype, we observed that pharmacological inhibition
of p110g in WT cells also results in defective IFN-g secre-
tion, whether IFN-g secretion is triggered through NK1.1
alone or together with IL-12 and IL-18 costimuli
(Figure S5). These data indicate that deficient activity of
p110g can affect IFN-g secretion by impairing down-
stream signaling of NK receptors.
Blockade of a 5-Lipoxygenase-Dependent
Pathway Inhibits ITAM-Dependent IFN-gSecretion
Because p110g is downstream of GPCRs signaling, the
requirement of p110g for NK1.1-elicited IFN-g secretion
implicated GPCRs in this effector function. To test this
hypothesis, we measured NK1.1-induced IFN-g secretion(C) Quantitative analysis of spleen NK cell phenotype inPik3cg/Pik3cd/ mice versus Pik3cg/Pik3cd//WT bone-marrow chimeras. The phe-
notype of spleen NK cells derived from Pik3cg/Pik3cd//WT or WT/WT chimeras is compared with the phenotype of spleen of
Pik3cg/Pik3cd/ and WT mice described in Figure 2. Every bar represents the average of 3–4 independent experiments. Data are represented
as the average + SEM. *p < 0.05; **p < 0.005. g/, Pik3cg/; d/, Pik3cd/; g/ d/, Pik3cg/Pik3cd/.Immunity 27, 214–227, August 2007 ª2007 Elsevier Inc. 219
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PI3K in NK Cell Development and FunctionFigure 4. NK Cell-Mediated Cytotoxicity Is Reduced in Pik3cg/Pik3cd/ Mice Ex Vivo and upon IL-2 Culture
(A and E) NK cells from Pik3cg/, Pik3cd/, Pik3cg/Pik3cd/, and WT mice were purified from spleen and used as such (A) or expanded for 8–
10 days in IL-2 (E). Equal numbers of cells were tested for their cytotoxicity against YAC-1 cells. Cytotoxicity was measured by standard chromium
release assay. One representative experiment out of four is shown.
(B) Proliferation of Pik3cg/,Pik3cg/Pik3cd/, andPik3cd/ NK cells in response to IL-2 stimulation. NK cells were purified from spleens and 105
cells/well were seeded in 96-well plates in the presence of high concentration of IL-2 (1000 U/ml). Proliferation was measured at day 3–4 by standard
3H-thymidine incorporation. One representative experiment out of three is shown.
(C) Expression of perforin and granzyme B in IL-2-cultured NK cells of WT,Pik3cg/, andPik3cg/Pik3cd/ mice. NK cells at day 5–7 of IL-2 culture
were stained with for NK1.1 and CD3, then fixed, permeabilized, and counterstained with anti-perforin and anti-granzyme B. A gate was placed on
NK1.1+CD3 cells.
(D) Phenotype of WT, Pik3cg/, Pik3cg/Pik3cd/, and Pik3cd/ NK cells upon IL-2 culture. Cells were analyzed by flow cytometry at day 5–7 of
IL-2 culture for expression of Ly49 receptors, NKG2D, and CD16. NK1.1+ CD3 cells were gated. One representative experiment out of three is
shown. Expression of CD127 was never detected in NK cells upon IL-2 culture (data not shown).
(F) Pharmacological blockade of p110g reduces NK cell lysis. The p110g inhibitor AS605240 was used in killing assays of YAC-1 cells by WT NK cells.
Similar results were obtained with the p110g inhibitor II AS604850 (data not shown). Pharmacological inhibitors were used at concentrations that
selectively block p110g (1 mM) (Camps et al., 2005). Results are representative of at least three independent experiments. g/, Pik3cg/;
d/, Pik3cd/; g/ d/, Pik3cg/Pik3cd/.in the presence of pharmacological inhibitors of GPCR
signaling (Figure 6D). Inhibitors included pertussis toxin
(PTX), which selectively blocks Gai, and a suramin analog,
NF023, which blocks Gao and Gai proteins. Moreover, we220 Immunity 27, 214–227, August 2007 ª2007 Elsevier Inc.tested MK-886, a specific inhibitor of the 5-lipoxygenase-
activating protein (FLAP). Together with 5-lipoxygenase
(5-LO) and LTA4 hydrolase (LTA4H), FLAP is a key media-
tor of the lipoxygenase pathway, which leads to the rapid
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(A–C) Pik3cg/, Pik3cd/, Pik3cg/Pik3cd/, and WT NK cells were expanded in IL-2 and then conjugated with fixed YAC-1 cells. Conjugates
were lysed and analyzed by immunoblotting with anti-phospho- and anti-total ERK, AKT, and p38. One experiment out of four is represented.
(D) Cytotoxicity of IL-2-expanded WT NK cells was tested against YAC-1 in the presence of the ERK inhibitor PD98059, the p38 inhibitor SB203580 or
the vehicle DMSO. These data are representative of at least three independent experiments. g/, Pik3cg/; d/, Pik3cd/; g/ d/,
Pik3cg/Pik3cd/.generation of leukotrienes (LT). These lipid mediators en-
gage GPCRs and have been previously shown to enhance
NK cell-mediated cytotoxicity (Cifone et al., 1993; Grazia
Cifone et al., 1997). PTX and NF023 did not inhibit
NK1.1-induced secretion of IFN-g (Figure 6D), possibly
because of the limited spectrum of G-proteins inhibited.
However, we found inhibition of IFN-g secretion with
MK-886 (Figure 6D). This result suggests that
crosslinking of NK1.1 induces a metabolic pathway that
generates lipid mediators, which in turn promote IFN-g
secretion by signaling through GPCRs and p110g. Cross-
linking of NK1.1 may also generate additional metabolites,
such as nucleotides or peptides, which may function as
GPCR ligands triggering IFN-g secretion.Because ITAM-mediated secretion of IFN-g requires
ERK activation in T cells (Berenson et al., 2006; Dong
et al., 2002; Egerton et al., 1996), we tested the ability of
pharmacological inhibitors of the ERK pathway to inhibit
NK1.1-induced secretion of IFN-g. Indeed, both the Ras
inhibitor FTI 277 and the MEK inhibitor PD98059 blocked
NK1.1-induced IFN-g secretion, whereas inhibition of
p38 with SB203580 had no effect (Figures 6D and 6E).
Thus, in NK cells, the pathway linking NK1.1 to IFN-g
secretion involves p110g, 5-lipoxygenase, and ERK. To
determine whether p110g is upstream or downstream of
ERK in this pathway, we crosslinked NK1.1 in Pik3cg/,
Pik3cd/, and WT NK cells ex vivo and measured ERK1
and ERK2 phosphorylation. We found that ERKImmunity 27, 214–227, August 2007 ª2007 Elsevier Inc. 221
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(A–C) Pik3cg/, Pik3cd/, Pik3cg/Pik3cd/, and WT splenocytes were stimulated ex vivo with plastic-coated anti-NK1.1 either in the absence
(A, B) or in the presence (C) of suboptimal concentrations of IL-12 and IL-18. IFN-g production was measured in DX5+CD3 NK cells by intracellular
staining (A, C) and cytometric bead array (B). These data are representative of at least four independent experiments.
(D and E) DX5-isolated NK cells were stimulated ex vivo with plastic-coated anti-NK1.1 as described above in the presence of the Gai inhibitor Per-
tussis Toxin (PTX), the Gao and Gai inhibitor suramin analog NF023, the FLAP inhibitor MK-886, the Ras inhibitor FTI-227, the ERK inhibitor PD98059,
the p38 inhibitor SB203580, or DMSO. IFN-g production was measured by cytometric bead array. These data are representative of at least three
independent experiments.
(F) Pik3cd/, Pik3cg/, and WT NK cells freshly isolated were stimulated with anti-NK1.1 and ERK activation was measured by immunoblot. One
representative experiment out of three is shown. g/, Pik3cg/; d/, Pik3cd/; g/ d/, Pik3cg/Pik3cd/.phosphorylation was not affected by p110g deficiency,
not only early after stimulation (Figure 6F) but also at later
time points (45 min, data not shown), suggesting that
p110g acts downstream of ERK. Together, these results
indicate that NK1.1-mediated IFN-g secretion requires
ERK activation. This event may initiate a metabolic path-
way that generates lipid mediators, such as leukotrienes,
that ultimately lead to IFN-g secretion by triggering
GPCR-p110g signals.
PI3Ks Inhibit the IL-12- and IL-18-p38 Pathway
of IFN-g Secretion in Murine NK Cells
Because IL-12 and IL-18 are the major stimuli that trigger
NK cell secretion of IFN-g, we investigated the impact of
PI3Ks on cytokine-induced IFN-g secretion. We stimu-222 Immunity 27, 214–227, August 2007 ª2007 Elsevier Inc.lated Pik3cg/, Pik3cd/, Pik3cg/Pik3cd/, and WT
splenocytes with optimal concentrations of IL-12 and IL-
18 and measured IFN-g in NK1.1+CD3 NK cells by intra-
cellular staining. Pik3cg/ NK cells produced IFN-g in
amounts comparable to WT NK cells (Figure 7A). A sub-
stantial increase in the production of IFN-g per cell, as
indicated by increased mean fluorescence intensity
(MFI), was noted in Pik3cd/ and Pik3cg/Pik3cd/
NK cells (Figure 7A). These results suggested that p110d
may inhibit cytokine-induced IFN-g production by NK
cells. Previous studies have shown that lack of the regula-
tory subunit of class IA PI3Ks, p85a, and pharmacological
inhibition of PI3K enzymatic activity result in augmented
DC secretion of IL-12 in response to TLR ligands, demons-
trating a role for PI3K as a negative regulator of TLR
Immunity
PI3K in NK Cell Development and FunctionFigure 7. IL-12- and IL-18-Induced IFN-g Secretion in NK Cells Is Regulated by a p38-Dependent ERK-Independent Pathway
(A) Pik3cg/, Pik3cd/, Pik3cg/Pik3cd/, and WT splenocytes were stimulated with IL-12 (1 ng/ml) and IL-18 (10 ng/ml). IFN-g production was
measured in NK1.1+CD3 NK cells by intracellular staining after 6 hr of culture. Similar results were observed in about 70% of Pik3cd/ and
Pik3cg/Pik3cd/ mice analyzed (7 mice/genotype).
(B) Lysates of WT, Pik3cg/, Pik3cd/, and Pik3cg/Pik3cd/ NK cells were analyzed by immunoblotting with anti-p85 and anti-ERK, as loading
control. One out of three representative experiments is shown.
(C) WT, Pik3cg/, and Pik3cd/ NK cells were stimulated with IL-12 (5 ng/ml) and IL-18 (25 ng/ml) for the indicated time, lysed, and analyzed by
immunoblotting with anti-phospho-p38, -phospho-JNK, -phospho-ERK. Anti-ERK and anti-PLC-g2 were used as loading control. One out of two
experiments with identical results is shown.
(D) WT NK cells were stimulated as described in (C) in the presence or in the absence of wortmannin. NK cell lysates were analyzed by immunoblotting
with an anti-phospho-p38 and anti-PLC-g2 as loading control. One out of two experiments with identical results is shown.
(E) WT splenocytes were stimulated with two different concentrations of IL-12 and IL-18 in the presence of PD98059, SB203580, or DMSO. IFN-g
production was measured by intracellular staining of DX5+CD3 NK cells and cytometric bead array. These data are representative of at least three
independent experiments. MFI, median fluorescence intensity; g/, Pik3cg/; d/, Pik3cd/; g/ d/, Pik3cg/Pik3cd/.signaling (Fukao et al., 2002). Because PI3K gene target-
ing has, in many cases, led to altered expression of the
nontargeted PI3K subunits (Vanhaesebroeck et al.,
2005), we assessed whether targeting of p110d hasa ‘‘knock-on’’ effect on the associated regulatory subunit
p85a. Expression of p85a was clearly reduced in
Pik3cd/ and Pik3cg/Pik3cd/ NK cells (Figure 7B),
suggesting that p110d may influence p85a expression,Immunity 27, 214–227, August 2007 ª2007 Elsevier Inc. 223
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complex. Altogether, our results demonstrate that p110d
regulates cytokine-induced IFN-g secretion, either di-
rectly or by modulating the expression of p85a.
PI3K inhibits TLR-induced cytokine secretion in DC by
blocking p38 activation (Fukao et al., 2002). Moreover,
pharmacological blockade of p38 activation inhibits
IL-12- and IL-18-induced secretion of IFN-g in NK cells
(Mavropoulos et al., 2005; Ortaldo et al., 2006). Thus, it
is possible that PI3Ks modulate IL-12- and IL-18-depen-
dent induction of IFN-g in NK cells by inhibiting p38 activa-
tion. Supporting this hypothesis, IL-12- and IL-18-induced
phosphorylation of p38 was increased in Pik3cd/ NK
cells in comparison with WT and Pik3cg/ NK cells
(Figure 7C). In contrast, ERK and JNK phosphorylation
were preserved (Figure 7C). p38 activation was also
boosted in WT NK cells upon treatment with the PI3K
inhibitor wortmannin (Figure 7D). Moreover, IL-12- and
IL-18-induced IFN-g secretion was inhibited by pharma-
cological blockade of p38, whereas blockade of ERK1
and ERK2 had no effect (Figure 7E). We conclude that,
although PI3Ks are required for ITAM-induced IFN-g
secretion, they negatively modulate cytokine-induced
IFN-g secretion by reducing p38 activation.
DISCUSSION
This study demonstrates that synergy between PI3K
catalytic subunits p110g and p110d is strictly required
for murine NK cell development. Although NK cells in
Pik3cd/mice appeared normal and a moderate develop-
mental defect was observed in Pik3cg/ mice, Pik3cg/
Pik3cd/ mice harbored reduced numbers of an aberrant
population of immature NK cells that do not acquire Ly49
receptors. The need for both p110g and p110d for normal
NK cell development is consistent with previous observa-
tions that both catalytic subunits are required for T cell
development (Swat et al., 2006; Webb et al., 2005). The
evidence that p110g signaling is necessary for a complete
NK cell maturation suggests the involvement of GPCRs in
this process. In line with these data, recent work indicates
that chemokines play a crucial role during B cell develop-
ment in the bone marrow, because they induce activation
ofadhesionmolecules that results inasustained interaction
of B cell precursors with stromal cells. Such sustained ad-
hesion is a PI3K-dependent process (Glodek et al., 2003).
In this context, we speculate that chemokines may trigger
GPCRs on NK cell precursors, inducing p110g-mediated
signals that activate integrins, prolonging the interaction
of NK cell precursors with their niche and thereby promot-
ing survival and proper differentiation.
How do we explain the synergy of p110g and p110d in
NK cell development? Several studies have shown that
certain chemokine receptors signal not only through
p110g but also through p110d (Curnock et al., 2003; Sot-
sios and Ward, 2000). These chemokine receptors can
recruit p110d either via Ga proteins or by activating p56
src kinases, which then recruit and activate p110d. If che-224 Immunity 27, 214–227, August 2007 ª2007 Elsevier Inc.mokine receptors involved in NK cell development signal
through p110g and p110d, lack of either p110g or p110d
would result in minimal or undetectable defects, but lack
of both p110g and p110d would determine a complete
abrogation of the signaling of these chemokine receptors
(Figure S6). Alternatively, deficit of p110dmay impair other
signaling pathways that contribute with GPCRs to NK cell
development. The generation of NK cell precursors and
their sequential differentiation and maturation is regulated
by multiple soluble and membrane factors (Di Santo,
2006; Lian and Kumar, 2002). Cytokines deliver signals
through disparate receptors, including the gc-dependent
receptors IL-15R and IL-7R and the tyrosine kinases
receptors c-kit and Flt3. These receptors recruit and acti-
vate class IA PI3K (Jiang et al., 2005; Koyasu, 2003; Young
et al., 2006). Cell-surface molecules expressed on stromal
cells also contribute to development of NK cells by stimu-
lating them through Tyro3 receptor tyrosine kinases (Car-
aux et al., 2006) and lymphotoxin b receptor (LTbR) (Lian
et al., 2004). Tyro3 receptor tyrosine kinases have been
shown to activate class IA PI3Ks (Lan et al., 2000). Thus,
p110d deficiency can lead to a defect in these develop-
mental pathways that contributes to the dramatic impair-
ment of NK development observed in Pik3cg/
Pik3cd/ mice (Figure S6).
Previous studies have implicated PI3K in NK cell-medi-
ated cytotoxicity based on indirect means of investigation,
including pharmacological inhibitors of PI3Ks (Bonnema
et al., 1994; Jiang et al., 2000; Zhong et al., 2002; Zompi
et al., 2003) and dominant-negative forms of PI3K target
molecules (Jiang et al., 2000). However, the PI3K family
members involved in NK cell effector functions were not
specifically identified. In our study, NK cell-mediated cyto-
toxicity was partially reduced in Pik3cg/Pik3cd/ mice,
formally demonstrating a requirement for both p110g and
p110d for receptor-mediated cytotoxicity. The defect
in cytotoxicity observed in Pik3cg/ and Pik3cg/
Pik3cd/ NK cells may be due to impaired maturation
of NK cells, which precludes normal acquisition of the cy-
tolytic capacity and expression of Ly49 receptors and
possibly yet unidentified activating receptors. However,
some defects in cytotoxicity persisted also when
Pik3cg/Pik3cd/ NK cells were activated with IL-2,
which restores normal NK cell cytolytic capacity by en-
hancing the expression of perforin and granzyme B. More-
over, cytotoxicity was partially reduced when WT NK cells
were treated with pharmacological inhibitors of p110g, in-
dicating that defective activity of p110g can impair NK cell
cytotoxicity, independently of the developmental defect.
A requirement for p110d for cytotoxicity was expected
when target cells engage activating NK cell receptors
that recruit class IA PI3K. Accordingly, a very recent study
showed that mice carrying a catalytically inactive mutant
form of p110d fail to reject transplanted lymphomas
(Saudemont et al., 2007). However, the contribution of
p110g is quite surprising because p110g signals down-
stream of GPCRs. It is possible that GPCRs, such as
chemokine receptors, generate inside-out signals that
activate integrins, which contribute NK cell cytotoxicity
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combined deficiency of p110g and p110d results in an
obvious reduction of cytotoxicity, p110d- and p110g-
mediated signals may be partially redundant. A previous
study showed that PI3Ks induce cytotoxicity through
sequential activation of Rac1, PAK1, MEK, and ERK (Jiang
et al., 2000). Consistent with this study, we showed a re-
duction of ERK1 and ERK2 activation in Pik3cg/
Pik3cd/ NK cells after conjugation with target cells.
However, lack of p110g and p110d did not completely
abrogate cytotoxicity or ERK activation. It is possible
that p110a and p110b can account for residual lytic func-
tions and ERK activation. Additionally, cytotoxicity and
ERK activation may occur independently of PI3K, as sug-
gested by recent studies showing that DAP10 can signal
not only via PI3Ks but also through recruitment of the
Grb-2-Vav1 complex (Figure S6; Upshaw et al., 2006).
NK cells employ two pathways to produce IFN-g, one
initiated by ITAMs and one by IL-12 and IL-18. Our study
demonstrates that these pathways are differentially
influenced by PI3Ks. IFN-g production induced through
the ITAM pathway requires p110g, suggesting the involve-
ment of GPCRs. Moreover, we observed that NK1.1-in-
duced IFN-g secretion is blocked by inhibitors of the
5-lipoxigenase pathway, which generates leukotrienes,
and by inhibitors of the ERK pathway, but not by p38 inhib-
itors. It is tempting to speculate that ITAM-mediated sig-
nals, particularly ERK phosphorylation, may initiate a met-
abolic pathway, which rapidly generates leukotrienes that
trigger GPCR-p110g signals and promote IFN-g produc-
tion (Figure S6). Consistent with this model, previous
work demonstrated a role for phospholypase A2 and 5-
LO in NKR-P1A-mediated and YAC-1-mediated cytotox-
icity in rat NK cells (Cifone et al., 1993; Grazia Cifone
et al., 1997).
In contrast to the ITAM pathway, the IL-12- and IL-18-
induced pathway for IFN-g production is modulated by
p110d. Previous studies have shown that PI3K acts as
a negative regulator of TLR-induced cytokine secretion
in DC (Fukao et al., 2002). Moreover, it has been shown
that PI3K acts by inhibiting p38 activation (Fukao et al.,
2002). Consistent with this model, we showed that
p110d deficiency and PI3K inhibitors increase cytokine-in-
duced phosphorylation of p38, whereas pharmacological
inhibitors of p38 block cytokine-induced production of
IFN-g in NK cells. We conclude that IL-12- and IL-18-
induced secretion of IFN-g in NK cells occurs through
a p38-dependent pathway, similar to that in T cells (Beren-
son et al., 2006), which is inhibited by p110d. p110d may
act either directly or by stabilizing expression of the asso-
ciated regulatory subunit p85a, resulting in increased PI3K
enzymatic activity. However, we cannot exclude that p85a
may also act as an adaptor capable of recruiting additional
inhibitory mediators.
Overall, our data demonstrate the importance of
converging signaling pathways mediated by p110g down-
stream of GPCRs and p110d downstream of activating
receptors and tyrosine kinases for murine NK cell devel-
opment and effector functions.EXPERIMENTAL PROCEDURES
Mice
Pik3cg/ and Pik3cd/ deficient mice have been previously de-
scribed (Jou et al., 2002; Sasaki et al., 2000) and were backcrossed
on to the C57BL/6 background until approximately 80% of the ge-
nomes were C57BL/6 homozygous as assessed by SSLP analysis.
The two mutant strains were intercrossed to generate Pik3cg/
Pik3cd/ mice. All animal studies were approved by the Washington
University animal studies committee.
Cell Cultures, Antibodies, and Flow Cytometry
NK cells were purified from spleens by positive selection with DX5
microbeads (Miltenyi Biotech). Ex vivo purified cells were stained
with antibodies specific for NK1.1, CD3, NKG2A,C,E, CD117,
CD127, CD122, CD11b, Ly49A, Ly49D, Ly49C,I, Ly49C,I,F,H, CD27,
2B4, CD69, CD16,32, IL-7Ra chain (PharMingen and eBioscience),
and NKG2D (Cella et al., 2004). Cells were expanded in IL-2 (1000 U/
ml) for 8–10 days. For detection of perforin and granzyme B, purified
cells were cultured in IL-2 for 5–6 days; surface labeled with anti-
NK1.1-APC and anti-CD3-FITC; fixed in 2% paraformaldhehyde for
10 min RT; permeabilized in 0.5% saponin, and counterstained with
anti-perforin-RPE (eBioscience) or anti-Granzyme B (Vosshenrich
et al., 2006). Before labeling, cells were always preincubated with
mAb 2.4G2 (ATCC) to block Fc-receptors.
Cytotoxicity Assays
Cytotoxicity against target cells was performed by standard chromium
release assay with either ex vivo purified NK cells or purified NK cells
cultured in IL-2 for 8–10 days as previously described (Cella et al.,
2004). In some experiments, cytotoxicity assays were performed in
the presence of the p110g inhibitor AS605240 or the p110g inhibitor
II AS604850 (Calbiochem). These inhibitors were used at 1 mM and
10 mM, respectively, which have been shown to specifically inhibit
p110g (Camps et al., 2005).
Bone-Marrow Chimeras
Recipient mice were irradiated with 950 rads of gamma irradiation to
ablate endogenous bone marrow 24 hr before adoptive transfer of do-
nor bone marrow. Donor bone marrow was isolated from the femurs
and tibia of mice, and the red blood cells were lysed with RBC lysis
buffer (Sigma). CD4+ and CD8+ T cells were eliminated by incubation
with anti-CD4 (IgM) and anti-CD8 (IgM) in PBS+5% BSA for 20 min
at 37C, followed by addition of 1 ml of rabbit complement (Cedar
Lane) and incubation for an additional 45 min at 37C. Cells were
washed 23 with PBS+5% BSA and resuspended in a small volume
of DMEM, and 107 cells were transferred to each host mouse intrave-
nously via the retro-orbital plexus. Mice were analyzed 8–9 weeks after
bone-marrow transplantation.
IFN-g Measurement
IFN-g was measured by intracellular staining or quantified by cytomet-
ric bead array (Mouse inflammation kit, BD). For intracellular staining,
cells from spleens of two mice for each genotype were pooled. 107 to-
tal splenocytes were stimulated in a well of 12-well plates coated with
purified NK1.1 (20 mg/ml, eBioscience) either in the absence or in the
presence of IL-12 (0.1 ng/ml) and IL-18 (1 ng/ml). When indicated,
PI3K p110g inhibitors were used to treat splenocytes 30 min before
and throughout the stimulation. After 2 hr, monensin (2 mM final) was
added to block cytokine egress. After 4 additional hours of culture,
cells were collected and Fc-receptors were blocked with mAb
2.4G2. Cells were surface labeled with anti-CD3-FITC, anti-CD19-
FITC, and either anti-DX5-RPE (when stimulated with anti-NK1.1) or
anti-NK1.1-RPE (when stimulated by IL-12 [PharMingen] and IL-18
[Peprotech]). Cells were then fixed and permeabilized as above and
counterstained with anti-IFN-g-APC. For cytometric bead arrays,
DX5-isolated NK cells were plated on 96-well plates coated with
anti-NK1.1 (50 mg/ml). Supernatants were collected after 15 hr andImmunity 27, 214–227, August 2007 ª2007 Elsevier Inc. 225
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were incubated in the presence of the inhibitor of ERK PD98059
(50 mM, Calbiochem), the inhibitor of Ras FTI-277 (50 mM, Calbiochem),
pertussis toxin (50 mg/ml, Calbiochem), the direct G protein antagonist
for a-subunit of the Go and Gi group suramin NF023 (50 mM, Calbio-
chem), and the inhibitor of 5-lipoxygenase-activating protein (FLAP)
MK886 (20 mM, Cayman).
Biochemical Analysis
Wild-type, Pik3cg/, Pik3cd/, and Pik3cg/Pik3cd/ NK cells
were cultured 5–8 days in IL-2. YAC-1 cells were fixed with glutharal-
deyde 0.05%. NK cells (1 3 106/sample) were mixed with fixed target
cells (E/T ratio 3:1). In some experiments, NK cells were stimulated ex
vivo with anti-NK1.1. In brief, NK cells were preincubated with mAb
2.4G2 to block Fc-receptors washed and incubated with NK1.1 for
15 min in ice. After washing, the cells were stimulated with a crosslink-
ing antibody and immediately lysed. Proteins from cell lysates were
separated by standard SDS-PAGE and analyzed by immunoblotting
with antibodies specific for phosphorylated and total ERK, AKT, and
p38. Anti-pERK1 and -pERK2 (Thr202/Tyr204), -pAKT (Ser473) and -
AKT, and -p38 and -phospho-p38 were from Cell Signaling; ERK
antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). Ex-
pression analysis of p85a, p110a, p110b, p110g, and p110d was per-
formed by immunoblotting of NK cell lysates with antibodies from
Santa Cruz Biotechnology and Upstate Biotechnology. The PI3K inhi-
bitor wortmannin (Sigma) was used at the indicated concentrations.
Supplemental Data
Six figures are available at http://www.immunity.com/cgi/content/full/
27/2/214/DC1/.
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